Nana
In a significant leap forward for medical technology, London-based HealthTech innovator Sava Technologies has successfully closed a €32.08 million ($36 million) Series B funding round. This latest injection of capital marks a pivotal transition for the company as it shifts its focus from research and development to large-scale manufacturing and commercialization. With a total funding footprint now reaching €60.6 million ($68 million), the startup is positioning itself as a formidable challenger to the status quo in continuous health monitoring.
The funding round was led by Ascensia, a global leader in diabetes care, with robust support from an impressive roster of institutional investors, including Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, and Pentland Ventures. Alongside the capital infusion, Sava announced a strategic partnership with Ascensia—a subsidiary of PHC Holdings Corporation—to serve as its primary commercialization and distribution arm, beginning in the European market.
The Evolution of Sava: A Chronological Journey
The story of Sava Technologies is one of rapid acceleration fueled by proprietary scientific breakthroughs. Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, the company spent five years operating in stealth mode, quietly perfecting a platform capable of detecting molecules just beneath the skin’s surface.
Key Milestones:
- 2019: Sava Technologies is founded by Circi and Michali, focusing on the development of next-generation microsensor technology.
- June 2024: After half a decade in development, the company emerges from stealth with a €7.4 million Seed round led by Balderton Capital and Exor Ventures.
- July 2025: Sava secures a €16.6 million Series A round, again led by Balderton Capital and Pentland Ventures, signaling investor confidence in the technology’s scalability.
- Early 2026: The company announces its €32.08 million Series B round and enters a strategic distribution agreement with Ascensia, setting the stage for imminent commercial rollout.
Breaking the Barrier: The Technology Behind the Sensor
The core of Sava’s value proposition lies in its radical departure from traditional Continuous Glucose Monitor (CGM) design. For decades, the industry has relied on relatively long filaments to track glucose levels in interstitial fluid. These traditional sensors can often cause physical discomfort or irritation, which impacts patient compliance.
Sava’s proprietary microsensors are approximately ten times shorter than the filaments found in conventional CGMs. By utilizing a "minimal-impact" design, the sensor reaches the necessary interstitial fluid with significantly less disruption to the skin, offering a virtually painless user experience.
However, the technology is designed to be more than a diabetes-management tool. While the current primary application is glucose monitoring, the platform’s underlying architecture is modular. By design, it can track a diverse array of biomarkers, potentially paving the way for continuous, real-time sensing of health metrics that extend far beyond metabolic health—covering everything from hormonal fluctuations to nutritional status and early disease detection.
Strategic Alliance: Partnering for Global Scale
The partnership with Ascensia is arguably as significant as the funding itself. Based in Basel, Switzerland, Ascensia is a giant in the diabetes management space, having been established in 2016 following the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. With a footprint spanning over 90 countries and direct commercial organizations in 29 markets, Ascensia brings the distribution muscle required to turn a technical breakthrough into a household consumer product.
For Sava, this partnership solves the "scale-up" dilemma—the common pitfall where startups possess revolutionary tech but lack the infrastructure to navigate complex medical device regulations and global supply chains. By leveraging the CONTOUR range’s existing commercial infrastructure, Sava aims to bypass years of market-building efforts.
Official Perspectives: Bridging Innovation and Clinical Need
The leadership teams at both Sava and Ascensia have emphasized that this partnership is rooted in a shared vision of simplifying life for patients with chronic conditions.
Renato Circi, co-founder and Co-CEO of Sava, highlighted the limitations of the current landscape: "For decades, continuous monitoring has been held back by the same legacy technology. This is about to change. We’re thrilled to be partnering with Ascensia, a global powerhouse in the space, to deliver, as a first step, something radically better to millions of people with diabetes."
Peter Bodlund, Chief Executive Officer of Ascensia, echoed this sentiment, underscoring the clinical importance of the collaboration: "Microsensor technology has the potential to transform the day-to-day monitoring experience for people with diabetes. By bringing together Sava’s innovative technology with Ascensia’s deep diabetes expertise, strong reputation and commercial capabilities, we have an exciting opportunity to address important unmet needs in diabetes care."
The Path to Commercialization: Clinical Hurdles and Market Entry
With the Series B funding secured, Sava is entering a critical phase of clinical validation. The company is preparing for a pivotal clinical study scheduled for later this year. The ultimate goal of this study is to secure CE approval for "non-adjunctive" use.
In the medical device world, achieving non-adjunctive status is the gold standard. It signifies that the device is accurate enough to be used for insulin dosing decisions without requiring the patient to perform a confirmatory "fingerstick" blood test. Achieving this certification will effectively cement the Sava device as a primary diagnostic and management tool, rather than a secondary support device.
Following potential CE approval, Ascensia is prepared to lead the commercial launch, with Europe serving as the primary beachhead. The company’s manufacturing strategy, which was designed from the outset for high-volume, low-cost production, is now being optimized to meet the expected demand of a large-scale launch.
Implications for the HealthTech Sector
The success of Sava Technologies and the validation provided by investors like Balderton Capital and Ascensia suggest a shifting trend in the HealthTech market. Investors are increasingly favoring companies that focus on "invisible" or "low-friction" diagnostics. The era of bulky, invasive health monitoring is clearly being eclipsed by technology that integrates seamlessly into daily life.
Long-term Implications:
- Democratization of Health Data: By making continuous monitoring less painful and more accessible, Sava is effectively pushing medical-grade diagnostics into the consumer sphere.
- Beyond Diabetes: The platform’s ability to pivot to other biomarkers could disrupt the wellness and preventative medicine sectors. If a user can monitor glucose, they could eventually monitor lactate, cortisol, or other vital indicators of physiological stress in real-time.
- Pressure on Legacy Players: The entrance of agile, high-tech startups like Sava puts significant pressure on legacy med-tech companies to innovate their own hardware or risk losing market share to superior, more comfortable user experiences.
Conclusion: A New Standard for Personalized Health
Sava Technologies represents the convergence of high-level bioengineering and consumer-centric design. By securing €32.08 million in Series B funding, the company is not just scaling its manufacturing; it is formalizing its role as a key player in the future of personalized medicine.
As the company prepares for its pivotal clinical trials, the medical community will be watching closely. If the microsensor technology performs as expected in clinical settings, it will not only provide a life-changing alternative for millions of people living with diabetes but also establish a new, high-efficiency blueprint for how medical devices are developed, distributed, and integrated into the daily lives of patients worldwide.
For now, the partnership between the London-based startup and the Swiss-based global powerhouse serves as a testament to the fact that when it comes to the future of health, the biggest breakthroughs often happen just beneath the surface.
Siti Muinah
Reynand Wu
